CSIMarket
 
Embecta Corp   (NASDAQ: EMBC)
Other Ticker:  
 
 
Price: $17.4200 $-0.31 -1.748%
Day's High: $18.07 Week Perf: -2.95 %
Day's Low: $ 17.09 30 Day Perf: -12.02 %
Volume (M): 468 52 Wk High: $ 21.23
Volume (M$): $ 8,153 52 Wk Avg: $14.68
Open: $17.72 52 Wk Low: $9.93



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 4,045
 Revenues (TTM) (Millions $) 1,106
 Net Income (TTM) (Millions $) 58
 Cash Flow (TTM) (Millions $) -25
 Capital Exp. (TTM) (Millions $) 13

Embecta Corp
The company is a global medical device company that focuses on providing solutions to improve the health and well-being of people living with diabetes. Their products are used by nearly 30 million people in over 100 countries for insulin administration and to aid with the daily management of diabetes. The company has a broad portfolio of marketed products, including a variety of pen needles, syringes, and safety injection devices. The company also seeks to promote advances in diabetes care through thought leadership and engagement with the diabetes community. They have three manufacturing sites located in Ireland, the United States, and China, and they distribute their products through a variety of channels, including retail, hospitals, pharmacies, and other institutional channels. The company uses a combination of patents, copyrights, trademarks, trade secrets, nondisclosure agreements, and other measures to establish and protect their proprietary rights.

In summary, the company is a leading global medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. With close to 100 years of experience in the industry, the company has become one of the most widely recognized and respected brands in diabetes management in the world.
The company's broad portfolio of products, including pen needles, syringes, and safety injection devices, as well as its proprietary digital application designed to assist people with managing their diabetes, has made a significant impact in diabetes care. The company's commitment to research and development, coupled with its global operations and strong financial performance, positions it for continued growth and success in the future.


   Company Address: 300 Kimball Drive, Suite 300 Parsippany 7054 NJ
   Company Phone Number: 401-0000   Stock Exchange / Ticker: NASDAQ EMBC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BDX   -4.4%    
• View Complete Report
   



Embecta Corp

Embecta Corp Reports Strong Q4 2024 Earnings bolstered by $21.60 Million Tax Provisions Amid Modest Revenue Growth

EMBC Reports Strong Earnings Despite Modest Revenue Growth in Q4 2024Embecta Corp (EMBC), a prominent player in the Medical Equipment & Supplies sector, has reported impressive earnings for the fourth quarter of 2024, showcasing a remarkable increase in earnings per share (EPS) despite relatively modest revenue growth. This performance highlights the company's ability to enhance profitability even in a challenging economic environment. Q4 Financial OverviewIn the fourth quarter of 2024, Embecta Corp achieved an EPS of $0.24, reflecting a remarkable year-over-year increase of 133.19%. This rise is noteworthy, given that it contrasts with a slight 1.847% increase in revenue, which reached $286.80 million compared to the same period in the prior year. However, compared to the previous financial quarter, EPS saw a marginal decline of 2.73% from $0.25 per share, while revenue surged by a healthy 5.402% from $272.10 million.

Dividend

Ringing Success: Embecta Declares Dividend Amid Financial Challenges and Diabetes Advocacy,

Published Tue, Nov 26 2024 11:00 AM UTC

Innovative Approaches Amid Financial Hurdles: Embecta Corp. Declares Quarterly Dividend and Rings Nasdaq Bell for Diabetes AwarenessIn a notable announcement from Embecta Corp., the New Jersey-based medical technology company has declared a quarterly cash dividend of $0.15 per share for its common stock, according to a press release dated November 26, 2024. This declaration ...

Management Announcement

Embecta Rings Nasdaq Bell for Diabetes Awareness Month While Navigating Financial Challenges with Innovative Solutions,

Published Thu, Nov 7 2024 11:30 AM UTC

November is National Diabetes Awareness Month, a time dedicated to raising awareness about diabetes and promoting better care solutions for those affected by this chronic disease. In a bold display of commitment to advancing diabetes management, Embecta Corp recently celebrated this important month by ringing the Nasdaq Closing Bell, joined by key diabetes advocacy groups. T...

Product Service News

Transforming Diabetes Care FDA Approves embectas Revolutionary Insulin Patch Pump for Type 2 Diabetes,

Published Tue, Sep 3 2024 10:30 AM UTC

Empowering Type 2 Diabetes Management: FDA Clears embecta s Revolutionary Disposable Insulin Patch PumpIn a landmark achievement poised to transform the landscape of diabetes care, embecta has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its innovative disposable insulin delivery system. This state-of-the-art patch pump, meticulously designe...

Dividend

Embecta Declares $0.15 Quarterly Dividend Amid Improved Financials and Reduced Payout Ratio,

Published Fri, Aug 9 2024 10:00 AM UTC

Embecta Corp. Boosts Shareholder Confidence with Quarterly Dividend Amid Strong Financial Performance
Embecta Corp., a prominent player in the healthcare sector, recently announced a quarterly cash dividend of $0.15 per share, reflecting its ongoing commitment to delivering value to shareholders. The dividend, which will be payable on September 13, 2024, is aimed at stoc...







Embecta's Segments
United States    52.7 % of total Revenue
International    47.3 % of total Revenue

  Embecta Outlook

On November 21 2023 the Embecta provided following guidance

Embecta Corp., a leading global diabetes care company, has recently released its financial results for the fourth quarter and full year of fiscal 2023. The company's report includes comprehensive information on its performance, as well as providing insights into its projected financial guidance for fiscal 2024.

Based on the report, Embecta Corp. achieved significant success during the three- and twelve-month periods ending on September 30, 2023. The company's financial results highlight its commitment to excellence in the field of diabetes care.

As a global leader in the industry, Embecta Corp. has demonstrated its ability to generate impressive revenue and achieve substantial growth. The compa...





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com